<DOC>
	<DOCNO>NCT03104842</DOCNO>
	<brief_summary>A Clinical Phase II , multicenter , Open-label study evaluate iNduction , consolidation maintenance treatment Isatuximab ( SAR650984 ) , Carfilzomib , LEnalidomide Dexamethasone ( I-KRd ) Primary diagnose high-risk multiple myeloma paTients</brief_summary>
	<brief_title>Evaluation iNduction , Consolidation Maintenance Treatment With Isatuximab , Carfilzomib , LEnalidomide Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Subjects must newly diagnose , untreated , symptomatic ( accord revise CRAB criterion 2014 ) , document myeloma measurable disease ( serum Mprotein ≥ 1 g/dL ( IgA ≥ 0.5 g/dL ) urine Mprotein ≥ 200 mg/24 hour ) case oligosecretory myeloma : involve FLC level ≥ 10 mg/dl , provide sFLC ratio abnormal case asecretory myeloma : &gt; 1 focal lesion measurable MRI Subjects must highrisk myeloma define follow : Presence one follow cytogenetic abnormality ( determined FISH ) : Del ( 17p ) ≥ 10 % purified cell ( 4 ; 14 ) &gt; 3 copy +1q21 ISS Stage II III ( patient ) FISH analysis external laboratory Heidelberg accept , list laboratory file study central . 2 . Must ≥ 18 year time signing informed consent form . 3 . Must able adhere study visit schedule protocol requirement investigator opinion . 4. WHO performance status 03 ( WHO=3 allow cause MM comorbid condition ) 5 . Females childbearing potential ( FCBP ) ( 1 ) must agree refrain become pregnant 28 day prior initiation study drug , study drug 30 days* discontinuation study drug use 2 reliable method contraception must agree regular pregnancy test timeframe . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) 3 ) achieve menarche point . 6 . Females must agree abstain breastfeed study participation 30 days* study drug discontinuation . 7 . Males must agree use latex condom sexual contact FCBP participate study 90 days* follow discontinuation study , even undergone successful vasectomy . 8 . Males must also agree refrain donate semen sperm treatment study drug 90 days* discontinuation study treatment . 9 . All subject must agree refrain donate blood study drug 28 day discontinuation study treatment . 10 . All subject must agree share medication . 11 . All participate subject follow requirement Lenalidomide Pregnancy Prevention Plan 1 . Contraindication require concomitant drug supportive treatment , include hypersensitivity antiviral drug . Known history allergy Captisol® ( cyclodextrin derivative use solubilize Carfilzomib ) , mannitol , sucrose , histidine ( base hydrochloride salt ) polysorbate 80 component study therapy amenable premedication steroid H2 blocker would prohibit treatment agent . 2 . Patients know systemic amyloidosis ( except AL amyloidosis skin bone marrow ) 3 . Administration systemic chemotherapy , biological , immunotherapy investigational agent ( therapeutic diagnostic ) multiple myeloma except bisphosphonate therapy . Emergency treatment dexamethasone allow cumulative dexamethasone dose less equal 160 mg . It allow include patient trial 1 cycle ( 4 week ) antimyeloma firstline treatment . 4 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/μL , unless relate myeloma Platelet count &lt; 30,000/ μL ( case platelets &lt; 50.000 /µl ≥ 30.000 /µl myeloma bone marrow infiltration ≥ 50 % ) Corrected serum calcium &gt; 14 mg/dL ( &gt; 3.5 mmol/L ) ; free ionized calcium &gt; 6.5 mg/dL ( &gt; 1.6 mmol/L ) Serum GOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) serum total bilirubin &gt; 2.0 mg/dL due hereditary abnormality Gilbert 's disease hereditary hemolysis ( Note : mention limit bilirubin ASAT/ALAT exceed , significant hepatic dysfunction investigator 's discretion , Tuebingen study office consult prior inclusion ) Patients severe renal impairment ( eGFR &lt; 30 ml/min/1.73 m² , MDRD formula CDKEPI Creatinine Clearance &lt; 30 ml/min ) 5 . Active congestive heart failure ( NYHA Class III IV ) , symptomatic cardiac ischemia , conduction abnormality uncontrolled conventional intervention . Myocardial infarction within four month prior study entry . 6 . Known HIV seropositive , hepatitis C infection , and/or hepatitis B ( except patient hepatitis B sAg core antibody receive respond antiviral therapy direct hepatitis B : patient allow ) . 7 . Acute active , uncontrolled infection 8 . Significant neuropathy ( Grades 3 4 , Grade 2 pain accord CTC V4.03 ) 9 . Second malignancy within past 5 year except : adequately treat basal cell squamous cell skin cancer carcinoma situ cervix prostate cancer Gleason Score ≤ 6 stable PSA past 12 month breast carcinoma situ full surgical resection treat medullary papillary thyroid cancer 10 . Patients pleural effusion require thoracentesis ascites require paracentesis within 14 day prior study entry . 11 . Major surgery within 4 week prior cycle 1 day 1 ( kyphoplasty consider major surgery ) ; subject fully recover surgical related toxicity . 12 . Female patient pregnant lactate 13 . Any clinically significant medical disease psychiatric condition , Investigator 's opinion , may interfere protocol adherence patient 's ability give inform consent . 14 . Participation clinical trial ( exclusion observational , noninterventional study ) )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>